Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1960107 | 1.00 | CYP3A4 (0.39) | CYP3A4PLA2G2APARP1GSK3BCDC7 | |
| SCHEMBL1960579 | 0.92 | GSK3B (0.40) | PARP1GSK3BCDC7ROCK2PIM1 | |
| SCHEMBL1837492 | 0.79 | PSD (0.39) | CYP3A4GSK3BROCK2MAPTKDM4E | |
| SCHEMBL1835187 | 0.78 | GSK3B (0.43) | CYP3A4GSK3BMAPTCYP2D6 | |
| SCHEMBL1840178 | 0.77 | GSK3B (0.39) | GSK3BCDC7ROCK2PIM1HIPK2 | |
| Oxalic Acid SCHEMBL1835999 | 0.77 | CYP2C9 (0.41) | GSK3BCDC7ROCK2PIM1HIPK2 | |
| SCHEMBL1835853 | 0.75 | GSK3B (0.39) | GSK3BCDC7ROCK2PIM1HIPK2 | |
| SCHEMBL1839402 | 0.73 | PRKDC (0.54) | PARP1GSK3BCDC7ROCK2PIM1 | |
| SCHEMBL1839427 | 0.67 | GSK3B (0.45) | GSK3BCDC7ROCK2PIM1HIPK2 | |
| SCHEMBL11610315 | 0.66 | KDM4E (0.48) | CLK4MAPTKDM4ENPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321313-B1 | SUBSTITUTED PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE DERIVATIVES AS GSK3 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-8211903-B2 | Substituted pyrimido isoquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20110144138-A1 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2138495-A1 | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144138-A1 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES | RECQL, QDPR, IFNAR1 | CYP3A4 1026/4885PLA2G2A 1611/4885PARP1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.